Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

This study is testing futibatinib — a targeted drug that blocks an abnormal protein called FGFR — in combination with other cancer treatments for patients with colorectal cancer and certain other solid tumors. The combination also includes immunotherapy and potentially chemotherapy. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with colorectal adenocarcinoma (colon or rectal cancer) confirmed by biopsy that is unresectable and/or metastatic - Your tumor has been tested for RAS, BRAF, and MSI status - You have not received any prior treatment in the advanced/palliative setting (first-line patients only for the colorectal cohort) - You are in reasonably good physical condition (ECOG 0-1) - Your blood counts and organ function are adequate - You agree to participate in accompanying research (tissue and blood samples) **You may NOT be eligible if...** - You have active brain tumors - You have significant heart problems - You have active inflammatory lung disease - You have received prior chemotherapy or immunotherapy for this stage of disease Talk to your doctor to see if this trial is right for you.